Immunotherapy in elderly patients: should we stay or should we go?

References

• 1. Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 19(6), e305–e316 (2018).
  MedlineGoogle Scholar
• 2. Pallis AG, Fortpied C, Wedding U et al. H. EORTC elderly task force position paper: approach to the older cancer patient. Eur. J. Cancer 46(9), 1502–1513 (2010).
  Medline CASGoogle Scholar
• 3. Hurria A, Levit LA, Dale W et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J. Clin. Oncol. 33(32), 3826–3833 (2015).
  MedlineGoogle Scholar
• 4. Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research. Am. Soc. Clin. Oncol. Educ. Book. 38, 400–414 (2018).
  MedlineGoogle Scholar
• 5. Müller L, Di Benedetto S, Pawelec G. The immune system and its dysregulation with aging. Subcell Biochem. 91, 21–43 (2019).
  Medline CASGoogle Scholar
• 6. Wagner A, Garner-Spitzer E, Jasinska J et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci. Rep. 8(1), 9825 (2018).
  MedlineGoogle Scholar
• 7. Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat. Rev. 45, 30–37 (2016).
  Medline CASGoogle Scholar
• 8. Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J. Immunother. Cancer 6(1), 26 (2018).
  MedlineGoogle Scholar
• 9. Kasherman L, Siu DHW, Lee KWC et al. Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: a meta-analysis. J. Geriatr. Oncol. 11(3), 508– 514 (2019).
  MedlineGoogle Scholar
• 10. Grossi F, Genova C, Crinò L et al. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. Eur. J. Cancer 123, 72–80 (2019).
  Medline CASGoogle Scholar
• 11. Youn B, Trikalinos NA, Mor V, Wilson IB, Dahabreh IJ. Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer 126(5), 978–985 (2020).
  Medline CASGoogle Scholar
• 12. Wang Y, Zhou S, Yang F et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 5(7), 1008–1019 (2019).
  MedlineGoogle Scholar
• 13. Wang DY, Salem JE, Cohen JV et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4(12), 1721–1728 (2018).
  MedlineGoogle Scholar
• 14. Corbaux P, Maillet D, Boespflug A et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur. J. Cancer 121, 192–201 (2019).
  Medline CASGoogle Scholar
• 15. Ridolfi L, De Rosa F, Petracci E et al. Anti-PD1 antibodies in patients aged ≥75years with metastatic melanoma: a retrospective multicentre study. J. Geriatr. Oncol. doi:S1879-4068(19)30356-X (2020). [Epub Ahead of Print]
  MedlineGoogle Scholar
• 16. Spigel D, Schwartzberg L, Waterhouse D et al. Is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of checkMate 153: topic: IT. J. Thorac. Oncol. 12(1), S1287–S1288 (2017).
  Google Scholar
• 17. van Holstein Y, Kapiteijn E, Bastiaannet E et al. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging 36(10), 927–938 (2019).
  Medline CASGoogle Scholar